JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

Search

BioCryst Pharmaceuticals Inc

Closed

SectorHealthcare

8.07 -1.94

Overview

Share price change

24h

Current

Min

8.02

Max

8.28

Key metrics

By Trading Economics

Income

27M

32K

Sales

14M

146M

Profit margin

0.022

Employees

580

EBITDA

22M

21M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+97.34% upside

Dividends

By Dow Jones

Next Earnings

4 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-123M

1.7B

Previous open

10.01

Previous close

8.07

News Sentiment

By Acuity

50%

50%

157 / 375 Healthcare

BioCryst Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

29 Jul 2025, 23:57 UTC

Acquisitions, Mergers, Takeovers

EQT: To Spend Y407.82B for Tender Offer

29 Jul 2025, 23:56 UTC

Acquisitions, Mergers, Takeovers

EQT: Tender Offer Price Is Y5,700 a Share

29 Jul 2025, 23:54 UTC

Acquisitions, Mergers, Takeovers

EQT To Start Tender Offer for Fujitec

29 Jul 2025, 23:50 UTC

Market Talk

Nikkei May Fall Amid Uncertainty Over Earnings, Domestic Politics -- Market Talk

29 Jul 2025, 23:36 UTC

Market Talk

Gold Steady Ahead of FOMC Decision -- Market Talk

29 Jul 2025, 22:57 UTC

Market Talk

Perseus May Step Up Capital Management at FY 2025 Result -- Market Talk

29 Jul 2025, 22:50 UTC

Market Talk

Mondelez Warns of Price Increases in North America -- Market Talk

29 Jul 2025, 22:44 UTC

Acquisitions, Mergers, Takeovers

St Barbara: Potential Divestment of Nova Scotia Ops to be Weighed in 1Q FY26

29 Jul 2025, 22:41 UTC

Acquisitions, Mergers, Takeovers

St Barbara FY25 All-in Sustaining Cost A$4,582/Oz

29 Jul 2025, 22:41 UTC

Acquisitions, Mergers, Takeovers

St Barbara 4Q All-in Sustaining Cost A$4,613/Oz

29 Jul 2025, 22:35 UTC

Earnings

IGO Maintains Nova Life of Mine Production Guidance

29 Jul 2025, 22:35 UTC

Earnings

IGO Expects FY 2026 Greenbushes Output of 1.50 Million-1.65 Million Tons

29 Jul 2025, 22:35 UTC

Earnings

IGO Expects FY 2026 Greenbushes Cash Costs of A$310-A$360/Ton

29 Jul 2025, 22:34 UTC

Earnings

IGO Expects Train 1 of Kwinana Refinery to Be Fully Impaired

29 Jul 2025, 22:34 UTC

Earnings

IGO Expects to Impair Kwinana Refinery Assets by A$70 Million-A$90 Million

29 Jul 2025, 22:34 UTC

Market Talk
Earnings

Mondelez Snack Demand Holding Up Better in Europe Than U.S. -- Market Talk

29 Jul 2025, 22:33 UTC

Earnings

IGO Had A$279.7 Million of Cash at End-June

29 Jul 2025, 22:33 UTC

Earnings

IGO 4Q Underlying Free Cash A$2.4 Million

29 Jul 2025, 22:33 UTC

Earnings

IGO FY Sales Revenue A$512.5 Million

29 Jul 2025, 22:33 UTC

Earnings

IGO 4Q Sales Revenue A$126.9 Million, Up 15% on 3Q

29 Jul 2025, 22:32 UTC

Earnings

IGO FY Nickel Production 17,173 Tons

29 Jul 2025, 22:32 UTC

Earnings

IGO 4Q Nickel Production 5,107 Tons, Up 22% on 3Q

29 Jul 2025, 22:32 UTC

Earnings

IGO 4Q Lithium Hydroxide Production 2,126 Tons, Up 36% on 3Q

29 Jul 2025, 22:31 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

29 Jul 2025, 22:31 UTC

Market Talk
Earnings

Mondelez Sees Consumers Trading Down, Buying in Bulk -- Market Talk

29 Jul 2025, 22:31 UTC

Earnings

IGO 4Q Spodumene Cash Cost A$366/Ton, Up 7% on 3Q

29 Jul 2025, 22:31 UTC

Earnings

IGO FY Spodumene Production 1.48 Million Tons

29 Jul 2025, 22:30 UTC

Earnings

IGO 4Q Spodumene Production 340,000 Tons, Flat on 3Q

29 Jul 2025, 22:30 UTC

Earnings

IGO 4Q Underlying Ebitda A$62 Million

29 Jul 2025, 22:22 UTC

Earnings

Starbucks Abandons Mobile Order, Pickup-Only Stores -- WSJ

Peer Comparison

Price change

BioCryst Pharmaceuticals Inc Forecast

Price Target

By TipRanks

97.34% upside

12 Months Forecast

Average 16.3 USD  97.34%

High 30 USD

Low 11 USD

Based on 10 Wall Street analysts offering 12 month price targets forBioCryst Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

9

Buy

1

Hold

0

Sell

Sentiment

By Acuity

157 / 375 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.